$BBIO 8-K SEC Filings

Filed On	Filing
13 Oct 2026	8-K: Other Events - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia
31 Aug 2026	8-K: Other Events
17 Aug 2026	8-K: Entry into a Material Definitive Agreement; Other Events
10 Aug 2026	8-K: Results of Operations and Financial Condition
22 Jul 2026	8-K: Other Events
02 Jul 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more
26 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
27 May 2026	8-K: Other Events
13 May 2026	8-K: Other Events
08 May 2026	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
07 May 2026	8-K: Results of Operations and Financial Condition; Other Events
30 Mar 2026	8-K: Other Events
24 Feb 2026	8-K: Results of Operations and Financial Condition
12 Feb 2026	8-K: Other Events
21 Jan 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
12 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
29 Oct 2025	8-K: Results of Operations and Financial Condition
29 Oct 2025	8-K: Other Events
27 Oct 2025	8-K: Other Events
05 Aug 2025	8-K: Results of Operations and Financial Condition

Comments